Antiremodeling effect of leukotriene receptor antagonist (pranlukast) in asthmatic subjects with chronic airflow limitation as assessed with computed tomography (CT).

Antiremodeling effect of leukotriene receptor antagonist (pranlukast) in asthmatic subjects with chronic airflow limitation as assessed with computed tomography (CT). - Antiremodeling effect of leukotriene receptor antagonist in asthmatic subjects.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000789

Enrollment

Registered

2007-08-10

Start date

2005-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

Treatment with pranlukast 450 mg for 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Perennial asthmatic patients visiting our outpatient clinic, who have been treated with inhaled corticosteroid and are stable for at least 6 months with FEV1<80% or FEV1/FVC<70% or %MMF<70% after inhalation of 200 mcg of salbutamol, and are never- or non-current nonsmokers with a smoking history of <5 pack-years, and were never treated with leukotriene receptor antagonists.

Exclusion criteria

Exclusion criteria: Subjects who suffered from respiratory tract infection in the previous month. Subjects who were taking NSAIDs.

Design outcomes

Primary

Measure	Time frame
Bronchial wall thickness, mean lung density, % low attenuation area	—

Secondary

Measure	Time frame
Pulmonary function tests Sputum eosinophil count Exhaled NO level Procollagen type 1 terminal peptide of sputum supernatant	—

Countries

Japan

Contacts

Public ContactHirofumi Matsuoka

Kyoto University Hospital Department of Respiratory Medicine

075-751-3830

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026